NeuroMetrix to Present at H.C. Wainwright BioConnect Conference 2022
January 05 2022 - 9:00AM
NeuroMetrix, Inc. (Nasdaq: NURO) announced today
that Shai N. Gozani M.D., Ph.D., President and Chief Executive
Officer, will be presenting at the H.C. Wainwright BioConnect
Conference to be held virtually on January 10-13, 2022. Dr.
Gozani’s video presentation will be available on-demand for 90 days
starting on Monday, January 10, 2022 at 7:00 A.M.
(ET). It may be accessed here and also on the NeuroMetrix, Inc.
Investor Relations page at www.NeuroMetrix.com. Dr. Gozani will
highlight the Company's product portfolio, growth initiatives and
outlook for 2022.
About NeuroMetrix
NeuroMetrix is an innovation-driven company focused on the
development and global commercialization of non-invasive medical
devices for the diagnosis and treatment of pain and neurological
disorders. The Company has three commercial products. DPNCheck® is
a diagnostic device that provides rapid, point-of-care detection of
peripheral neuropathies. ADVANCE® is a diagnostic device that
provides automated, in-office nerve conduction studies for the
evaluation of focal neuropathies. Quell® is a wearable
neurostimulation device indicated for treatment of lower extremity
chronic pain. For more information, visit www.NeuroMetrix.com/.
NeuroMetrix, Inc.Thomas T. Higgins, 781-314-2761SVP and Chief
Financial Officerneurometrix.ir@neurometrix.com
Source: NeuroMetrix, Inc.
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Aug 2024 to Sep 2024
NeuroMetrix (NASDAQ:NURO)
Historical Stock Chart
From Sep 2023 to Sep 2024